H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)

April 15, 2026 7:19 AM

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $70.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found